Smart drugs are targeted therapies developed to act on specific targets of cancer cells, differing from classic chemotherapy. Focused on genetic and molecular structures, these treatments cause less harm to healthy cells. Smart drugs generally include groups such as immunotherapy, monoclonal antibodies, tyrosine kinase inhibitors, and biological agents.
Key Features of Smart Drugs
-
Targeted therapy
-
Personalized medicine approach
-
Relatively fewer side effects
-
Often requires long-term use
-
Belongs to high-cost drug groups
| Characteristic | Classic Chemotherapy | Smart Drug |
|---|---|---|
| Mode of Action | Suppresses cell division | Focuses on a specific target |
| Side Effects | High | Lower |
| Duration of Use | Limited, curative intent | Long-term |
| Cost | Relatively low | Very high |
Does SGK Cover Smart Drugs?
Does SGK cover smart drugs? The answer is “Yes, but under specific conditions.” As of 2026, SGK has included some smart cancer drugs in its reimbursement list, while others are covered partially or with indication limitations.
SGK Payment Criteria
-
Being listed in the SUT (Healthcare Implementation Communiqué)
-
Oncology medical board report
-
Matching the specified cancer type and stage
-
Having tried alternative treatments where required
-
Proper prescription and report validity periods
| Payment Status | Explanation |
|---|---|
| Fully Covered | Included in SUT and documented with report |
| Partially Covered | Patient pays co-payment/difference fee |
| Not Covered | Usage outside approved indication |
Smart Drugs Listed in the 2026 SGK Reimbursement List
The 2026 SGK list shows a limited but selective expansion compared to the previous year. Priority has been given to advanced-stage cancers, treatment-resistant tumors, and metastatic cases.
| Drug Group | Usage Area | SGK Status |
|---|---|---|
| Immunotherapy Drugs | Lung, skin, kidney | Conditional |
| Monoclonal Antibodies | Breast, colon | Partial |
| Tyrosine Kinase Inhibitors | Leukemia | Largely covered |
| Biological Agents | Rare cancers | By report |
Which Smart Drugs Are Not Covered by SGK?
SGK does not reimburse for off-label usage, experimental treatments, or drugs still in clinical research. Additionally, some medications sourced through international procurement may fall outside reimbursement rules.
Reasons for Non-Coverage
-
Drugs not listed in SUT
-
SGK approval not given despite FDA approval
-
Chosen despite available alternative treatments
-
Report validity expired
| Reason | Explanation |
|---|---|
| Off-Label Use | SGK does not reimburse |
| Experimental Drug | Still in clinical phases |
| International Procurement | Exceptional cases, may not be reimbursed |
Report and Prescription Requirements for Smart Drugs
The most critical element for SGK reimbursement of smart drugs is the medical board report. Reports are typically issued for 3, 6, or 12 months and are prepared by oncology specialists.
Required Documents
-
Oncology medical board report
-
Pathology and genetic test results
-
Treatment protocol
-
E-prescription
| Document | Requirement |
|---|---|
| Medical Board Report | Mandatory |
| Genetic Test | Required for most drugs |
| Pathology Report | Mandatory |
Smart Drug Prices and SGK Contribution
Smart drug prices can range monthly from approximately 50,000 TL to 300,000 TL. If SGK does not fully cover the cost, a patient contribution may apply.
| Drug Type | Average Monthly Cost | SGK Contribution |
|---|---|---|
| Immunotherapy | 120,000 TL | 70%–90% |
| Targeted Therapy | 80,000 TL | 60%–80% |
| Biological Agent | 200,000 TL | Limited |
Differences Between Private and Public Hospitals
Public hospitals generally apply SGK coverage more directly, while in private hospitals additional charges such as drug price differences, service fees, and other extra expenses may arise.
| Hospital Type | Extra Fees |
|---|---|
| Public Hospital | None |
| University Hospital | Limited |
| Private Hospital | High |
Legal Actions and Appeals for Smart Drugs
Patients can pursue legal action when SGK does not cover a smart drug. Precautionary injunctions have enabled many patients to access medications free of charge while cases proceed.
Stages of the Legal Process
-
Obtain SGK rejection letter
-
Collect medical reports
-
File an administrative court application
-
Request a precautionary injunction
Frequently Asked Questions
Does SGK cover all smart drugs?
No. Only those included in the SUT and meeting specific conditions are covered.
Were new smart drugs added in 2026?
Yes. Some immunotherapy and targeted drugs were added to the list in a limited way.
How long is the report validity for smart drugs?
Typically between 3 and 12 months.
What can be done for drugs not covered by SGK?
Filing an administrative court case and requesting a precautionary injunction is possible.
Will private hospitals charge extra for smart drugs?
Yes. Private hospitals may apply additional fees and price differences for medications.